Latest papers

Glufosfamide: beta-D-Glc-IPM, D 19575.

Determination of glufosfamide in rat plasma by liquid chromatography/tandem mass spectrometry.

Metabolism and transport of oxazaphosphorines and the clinical implications.

1,3- vs 1,5-intramolecular alkylation reactions in isophosphoramide and phosphoramide mustards.

Diminishing the risk of nonrelapse mortality in hematopoietic stem cell transplantation: Prediction of exposure to the cyclophosphamide metabolite carboxyethylphosphoramide mustard.

Sulfonyl-containing aldophosphamide analogues as novel anticancer prodrugs targeted against cyclophosphamide-resistant tumor cell lines.

Hypersensitivity pneumonitis associated with the use of trofosfamide.

Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancera phase II trial of the EORTC-New Drug Development Group

[Cytostatic effects of bifolar and chlofiden. Effect on protein synthesis and cell cycle].

1,2-benzisoxazole phosphorodiamidates as novel anticancer prodrugs requiring bioreductive activation.

European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme.

Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy.

Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group.

Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation.

Phosphate prodrugs of isophosphoramide mustard.

Glufosfamide (Baxter Oncology).

Design, synthesis, and biological evaluation of indolequinone phosphoramidate prodrugs targeted to DT-diaphorase.

Isophosphoramide mustard analogues as prodrugs for anticancer gene-directed enzyme-prodrug therapy (GDEPT).

In vitro activity of glufosfamide in childhood acute leukemia.

In vitro activity of oxazaphosphorines in childhood acute leukemia: preliminary report.